Figure legends
Figure 1 . Comprehensive summary data on COVID-19 clinical trials completed, in progress, or in advanced planning stages as of April 17, 2020. Trial data were organized according to drug and target or pharmacologic mechanism, along with results and pertinent literature from any preliminary COVID-19 studies (or prior SARS and MERS studies), trial ID and phase, and data on investigational scale and structure including number of participants, blinding, single vs. multi-center status, and estimated completion date.
Figure 2 . Cumulative statistics from current COVID-19 clinical trials, based on the aggregate number of trials (out of a total of 53 publicly reported by April 17, 2020) involving (A) a specific drug, (B) a classifying target or mechanism, (C) clinical research phase, (D) single center vs. multi-center, and (E) a given expected timeframe for reporting results.
Figure 3 . Summary data on promising untested candidates for COVID-19 drug repurposing based on proven success in SARS and/or MERS in vitro studies, with focus on target selectivity, viral load reduction, and number of positive reports with independent confirmation.